It is also approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring as well as to lower the risk of heart attack, stroke, and death from heart disease in adults with heart disease and overweight or obesity
Most patients notice improvement within the first few weeks
For patients starting GLP-1 therapy For patients adjusting doses For patients tracking side effects or progress For patients who love data (or just a little structure) Keep going
3 During these trials, which investigated the utility of these drugs for glycemic control, GLP-1RAs showed a secondary benefit of weight reduction, which has led to their recent approval for weight management in several countries worldwide
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
When the FDA determines a patent-protected drug is in shortage, pharmacies are permitted to compound copies of the drug